12 Weeks to Better Vision Online Coaching Program

Learn More  
EyeHealthInstitute Logo
In-office intensiveTelehealthOnline course

Last updated on Sep 29, 2025

Retinitis Pigmentosa: Updated Treatment Options for 2026

A roundup of late-stage and emerging treatments for retinitis pigmentosa heading into 2026—pros, cons, and what’s in the news.

Retinitis Pigmentosa: Updated Treatment Options for 2026

If you or a loved one is living with retinitis pigmentosa, the landscape is changing. Multiple late-stage programs and new modalities are moving toward pivotal readouts and regulatory milestones in 2025–2026. Below is a roundup of what’s in the news now, with potential pros and cons of each approach.

This article summarizes current developments and does not provide medical advice. Discuss personal options with your eye-care team.

1) Modifier Gene Therapy (OCU400, Ocugen)

What it is. A single-dose AAV-based “modifier” gene therapy (NR2E3) designed to improve retinal homeostasis across multiple RP genotypes; currently in Phase 3 and recruiting (NCT06388200). Ocugen has publicly indicated a potential BLA timing beginning in 2026 if data support it. Potential pros.

  • Gene-agnostic design may broaden eligibility beyond a single mutation. - Late-stage trial with functional mobility endpoints may clarify real-world benefit.

Potential cons.

  • Requires subretinal surgery in many gene therapy paradigms; procedural risks apply.
  • Efficacy and durability must be confirmed in Phase 3; results pending.

2) Optogenetic Gene Therapy (Gene-Agnostic)

What it is. Delivers light-sensing molecules to surviving inner-retinal cells so they can respond to light, independent of the original photoreceptors. Leading programs: MCO-010 (Nanoscope) with rolling BLA initiated in 2025, and GS030 (GenSight) with continuing PIONEER follow-up and additional dose-escalation work.

Potential pros.

  • Mutation-agnostic; intended for advanced RP with minimal photoreceptor function.
  • Intravitreal delivery (MCO-010) may avoid subretinal surgery.

Potential cons.

  • Some platforms require wearable light-stimulating goggles for optimal activation.
  • Visual gains have been variable across early studies; larger controlled data and regulatory review are in progress.

3) RPGR Gene Therapy for X-Linked RP (XLRP)

What it is. For RP caused by RPGR variants. Beacon Therapeutics’ laru-zova reported positive interim data (SKYLINE/DAWN; Phase 2/2–3), while botaretigene sparoparvovec (J&J/MeiraGTx) failed its Phase 3 LUMEOS primary endpoint in May 2025.

Potential pros.

  • Gene replacement directly targets the root cause in XLRP.
  • Positive interim signals may support progression to late-stage outcomes.

Potential cons.

  • Mixed results across programs underscore uncertainty; one Phase 3 failed its primary endpoint.
  • Typically subretinal delivery with associated surgical considerations.

4) Cell Therapy (Retinal Progenitor Cells; jCell, jCyte)

What it is. Allogeneic retinal progenitor cell suspension injected intravitreally to release trophic factors and potentially preserve or improve function. A new Phase 2 study began dosing in 2025 at a higher cell dose, with broader genotype eligibility.

Potential pros.

  • Gene-agnostic; may be applicable across RP subtypes.
  • Intravitreal route avoids subretinal surgery.

Potential cons.

  • Prior trials suggested signals but did not yield an approved product; efficacy confirmation still needed.
  • Immune response and durability remain key questions under study.

5) Antioxidant / Pharmacologic Approaches

N-Acetylcysteine (NAC) – “NAC Attack,” Phase 3. Johns Hopkins launched a multinational Phase 3 trial (≈438 patients) testing high-dose oral NAC to slow RP progression.

Potential pros.

  • Large, randomized design may clarify real-world benefit and safety.

Potential cons.

  • Prior supplement strategies (e.g., high-dose vitamin A) have recently been re-evaluated, with updated analyses finding no overall benefit and continued caution about vitamin E.

N-acetylcysteine-amide (NACA; Nacuity). Early-stage trials and foundation funding continue for this gene-agnostic antioxidant approach.

6) CRISPR Gene Editing (Preclinical/Early Translation)

What it is. EDIT-103 is a dual-AAV “knock-out and replace” strategy targeting RHO-associated autosomal dominant RP; public updates remain preclinical/early-translation.

Potential pros.

  • Designed to address many RHO mutations with a single construct.

Potential cons.

  • As of now, clinical efficacy data are not yet available; regulatory timelines are uncertain.

7) Neurostimulation / Electrical Stimulation

What it is. Corneal, transpalpebral, or alternating-current electrical stimulation aiming to modulate retinal activity and neurotrophic signaling. Recent literature includes prospective randomized TES/TpES studies and systematic reviews.

Potential pros.

  • Non-gene-specific modality; signals of improved fields/ERG reported in some controlled trials.

Potential cons.

  • Heterogeneous protocols and small samples; authors call for larger RCTs and parameter standardization.

Note: Electrical/alternating-current stimulation is a modality also used in our clinic (e.g., ACS-style approaches) as part of integrative care plans.

8) Photobiomodulation (PBM; Red-Light Therapy)

What it is. Low-level light (typically 630–800 nm) targeted to improve mitochondrial function and reduce oxidative stress. PBM has growing evidence in retinal disease; RP-specific pilot data and broader reviews were published in 2024–2025.

Potential pros.

  • Non-invasive; early reports suggest functional gains in select cohorts.

Potential cons.

  • RP data remain limited; dosing protocols and durability require further study.

9) Hyperbaric Oxygen Therapy (HBOT)

What it is. Pressurized oxygen exposure to increase retinal oxygen availability; historic and review-level reports note potential physiological rationale, but evidence is limited and mixed.

Potential pros.

  • The retina is highly oxygen-demanding; HBOT may increase tissue oxygenation.

Potential cons.

  • Mixed findings across ocular conditions; more RP-specific, modern RCTs are needed.

How This Ties Into Holistic, Integrative Care

Many of the above innovations are gene-agnostic or adjunctive, aligning with a comprehensive, systems-level approach that focuses on circulation, oxygenation, mitochondrial support, and inflammation control—pillars emphasized in our clinic through ophthalmic acupuncture, alternating-current microstimulation, nutritional and herbal strategies, stress reduction, and red-light therapy, alongside your retina specialist’s standard care. These are complementary, and plans should be individualized with your providers.

Next Steps

The treatment pipeline for RP is actively advancing, with multiple late-stage trials, regulatory designations, and emerging modalities that look promising heading into 2026. If you’d like a personalized plan that integrates these developments with holistic vision care:

We’re here to help you navigate options, protect what you have, and make the most of new breakthroughs.